主页

首页 - 支持与资源 - 发表文献

2020. 04NGS

Polymorphisms and rare variants identified by next-generation sequencing confer risk for lung cancer in han Chinese population

Li Xiaoqi, Liu Jinsheng, Wang Ke, Zhou Juan, Zhang Hang, Zhang Mancang, Shi Yongyong

阅读全文

ABSTRACT

Background: Lung cancer is one of the leading causes of cancer death worldwide, and genetic risk factors account for a large part of its carcinogenesis. The low economic requirements and high efficiency of next-generation sequencing (NGS) make it widely used in detecting genetic alterations in pathogenesis.

Methods: We performed targeted panel sequencing in 780 Han Chinese lung cancer patients using a commercial probe, and the correlations between dozens of susceptible sites were verified in 1113 healthy controls. This study used Fisher's exact test and Benjamini-Hochberg FDR correction to analyze the mutual exclusion between mutated genes, and Pearson's p was used to verify the correlations between mutations and lung cancer susceptibility.

Results: Our results determined the mutation spectrum and showed that each lung cancer patient carried at least one DNA mutation. The most frequently mutated gene was BRCA2 (mutation rate,10.6 %.). The co-occurrence and mutual exclusion analysis of DNA damage related genes showed that gene ATM was mutually exclusive from MSH6. We conducted a further case-control study in different subtypes of lung cancer and the results described 14 mutations associated with adenocarcinoma, 9 with squamous cell carcinoma, and 4 with small cell lung cancer. These variants were novel de-novo germline mutations in lung cancer. Particularly, rs3864017 in FANCD2 showed a protective effect of lung adenocarcinoma for carriers (OR=0.146, 95 % CI=0.052∼0.405, Padjusted=3.37×10−4).

Conclusions: 18 candidate mutations might alter the risk of lung cancer in the Han Chinese population, including polymorphisms rs3864017(FANCD2), rs55740729(MSH6) and 16 rare variants. The underlying mechanisms of candidate genes in lung cancer remain unclear and we suggest more functional studies on exploring how these genes affect the risk of lung cancer.

相关文章

迪赢合成—生命科学“核”动力

联系我们

电话:400-017-9077

地址:上海市闵行区光华路248号5号楼2楼

邮箱:zhengyuqing@dynegene.com

关注我们

Copyright © 2025 上海迪赢生物科技有限公司
All rights reserved.    沪ICP备2021008439号-2

网站地图 I 隐私政策